Abstract
Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR associated (Cas) protein has been proved as a powerful tool for the treatment of genetic diseases. The Cas9 protein, when combined with single-guide RNA (sgRNA), forms a Cas9/sgRNA ribonucleoprotein (RNP) capable of targeting and editing the genome. However, the limited availability of effective carriers has restricted the broader application of CRISPR/Cas9 RNP. In this study, we evaluated dual pH-responsive amphiphilic xenopeptides (XPs) for delivering CRISPR/Cas9 RNP. These artificial lipo-XPs contain apolar cationizable lipoamino fatty acid (LAF) and polar cationizable oligoaminoethylene acid units such as succinoyl-tetraethylenepentamine (Stp) in various ratios and U-shaped topologies. The carriers were screened for functional Cas9/sgRNA RNP delivery in four different reporter cell lines, including a Duchenne muscular dystrophy (DMD) exon skipping reporter cell model. Significantly enhanced cellular uptake into HeLa cells, effective endosomal disruption in HeLa gal8-mRuby3 cells, and potent genome editing by several Cas9/sgRNA RNP complexes was observed in four different cell lines in the 5 nM sgRNA range. Comparing Cas9/sgRNA RNP complexes with Cas9 mRNA/sgRNA polyplexes in the DMD reporter cell model demonstrated similar splice site editing and high exon skipping of the two different molecular Cas9 modalities. Based on these studies, analogues of two potent U1 LAF2-Stp and LAF4-Stp2 structures were deployed, tuning the amphiphilicity of the polar Stp group by replacement with the six oligoamino acids dmGtp, chGtp, dGtp, Htp, Stt, or GEIPA. The most potent LAF2-Stp analogues (containing dGtp, chGtp or GEIPA) demonstrated further enhanced gene editing efficiency with EC50 values of 1 nM in the DMD exon skipping reporter cell line. Notably, the EC50 of LAF2-dGtp reached 0.51 nM even upon serum incubation. Another carrier (LAF4-GEIPA2) complexing Cas9/sgRNA RNP and donor DNA, facilitated up to 43% of homology-directed repair (HDR) in HeLa eGFPd2 cells visualized by the switch from green fluorescent protein (eGFP) to blue fluorescent protein (BFP). This study presents a delivery system tunable for Cas9 RNP complexes or Cas9 RNP/donor DNA polyplexes, offering an effective and easily applicable strategy for gene editing.
| Original language | English |
|---|---|
| Article number | 106983 |
| Pages (from-to) | 106983 |
| Journal | European Journal of Pharmaceutical Sciences |
| Volume | 205 |
| Early online date | 6 Dec 2024 |
| DOIs | |
| Publication status | Published - 1 Feb 2025 |
Funding
The authors acknowledge support by the UPGRADE (Unlocking Precision Gene Therapy) project that has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 825825. This work was also supported by the German Research Foundation (DFG) SFB1032 (project-ID 201269156) sub-project B4, and BMBF Cluster for Future \u2018CNATM - Cluster for Nucleic Acid Therapeutics Munich\u2019 project number 03ZU1201AA. X.L. appreciates the fellowship of the China Scholarship Council that supports his Ph.D. study. We thank Susanne Kempter (Faculty of Physics, LMU Munich) for performing TEM measurements, Eric Weidinger for scientific discussions, Wolfgang R\u00F6dl and Olga Br\u00FCck (Pharmaceutical Biotechnology, LMU Munich) for technical and organizational support.
Austrian Fields of Science 2012
- 301208 Pharmaceutical technology
- 210002 Nanobiotechnology
Keywords
- Cas9/sgRNA ribonucleoprotein
- CRISPR Cas9
- Genome editing
- Homology-directed repair
- Lipo-xenopeptide